{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:11:48Z","timestamp":1759342308672,"version":"3.37.3"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T00:00:00Z","timestamp":1601769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T00:00:00Z","timestamp":1601769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Research Fund of Istanbul University- Cerrahpasa","award":["58745","27781","26989"],"award-info":[{"award-number":["58745","27781","26989"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuromol Med"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s12017-020-08619-x","type":"journal-article","created":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T20:03:21Z","timestamp":1601841801000},"page":"292-304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Low Levels of LRRK2 Gene Expression are Associated with LRRK2 SNPs and Contribute to Parkinson\u2019s Disease Progression"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5870-2334","authenticated-orcid":false,"given":"Selma","family":"Y\u0131lmazer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esin","family":"Canda\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gen\u00e7er","family":"Gen\u00e7","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merve","family":"Alayl\u0131o\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00fc\u015fra","family":"\u015eeng\u00fcl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ay\u015feg\u00fcl","family":"G\u00fcnd\u00fcz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00fclya","family":"Apayd\u0131n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcne\u015f","family":"K\u0131z\u0131ltan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibel","family":"Ertan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erdin\u00e7","family":"Dursun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duygu","family":"Gezen-Ak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,4]]},"reference":[{"issue":"5","key":"8619_CR1","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/ana.20456","volume":"57","author":"JO Aasly","year":"2005","unstructured":"Aasly, J. O., Toft, M., Fernandez-Mata, I., Kachergus, J., Hulihan, M., White, L. R., et al. (2005). Clinical features of LRRK2-associated Parkinson\u2019s disease in central Norway. Annals of Neurology, 57(5), 762\u2013765. https:\/\/doi.org\/10.1002\/ana.20456.","journal-title":"Annals of Neurology"},{"issue":"4","key":"8619_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/0891988716640373","volume":"29","author":"M Alaylioglu","year":"2016","unstructured":"Alaylioglu, M., Gezen-Ak, D., Dursun, E., Bilgic, B., Hanagasi, H., Ertan, T., et al. (2016). The association between clusterin and APOE polymorphisms and late-onset Alzheimer disease in a Turkish cohort. Journal of Geriatric Psychiatry and Neurology, 29(4), 221\u2013226. https:\/\/doi.org\/10.1177\/0891988716640373.","journal-title":"Journal of Geriatric Psychiatry and Neurology"},{"issue":"7","key":"8619_CR3","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00702-010-0423-6","volume":"117","author":"S Bardien","year":"2010","unstructured":"Bardien, S., Marsberg, A., Keyser, R., Lombard, D., Lesage, S., Brice, A., et al. (2010). LRRK2 G2019S mutation: Frequency and haplotype data in South African Parkinson\u2019s disease patients. Journal of Neural Transmission, 117(7), 847\u2013853. https:\/\/doi.org\/10.1007\/s00702-010-0423-6.","journal-title":"Journal of Neural Transmission"},{"issue":"12","key":"8619_CR4","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1007\/s00115-008-2542-y","volume":"79","author":"H Braak","year":"2008","unstructured":"Braak, H., & Del Tredici, K. (2008). A new look at the corticostriatal-thalamocortical circuit in sporadic Parkinson\u2019s disease. Nervenarzt, 79(12), 1440\u20131445. https:\/\/doi.org\/10.1007\/s00115-008-2542-y.","journal-title":"Nervenarzt"},{"issue":"1","key":"8619_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","volume":"318","author":"H Braak","year":"2004","unstructured":"Braak, H., Ghebremedhin, E., Rub, U., Bratzke, H., & Del Tredici, K. (2004). Stages in the development of Parkinson\u2019s disease-related pathology. Cell and Tissue Research, 318(1), 121\u2013134. https:\/\/doi.org\/10.1007\/s00441-004-0956-9.","journal-title":"Cell and Tissue Research"},{"issue":"6","key":"8619_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/jhg.2014.26","volume":"59","author":"LF Cardo","year":"2014","unstructured":"Cardo, L. F., Coto, E., Ribacoba, R., Mata, I. F., Moris, G., Menendez, M., et al. (2014). The screening of the 3\u2019UTR sequence of LRRK2 identified an association between the rs66737902 polymorphism and Parkinson\u2019s disease. Journal of Human Genetics, 59(6), 346\u2013348. https:\/\/doi.org\/10.1038\/jhg.2014.26.","journal-title":"Journal of Human Genetics"},{"key":"8619_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41531-017-0010-8","volume":"3","author":"DA Cook","year":"2017","unstructured":"Cook, D. A., Kannarkat, G. T., Cintron, A. F., Butkovich, L. M., Fraser, K. B., Chang, J., et al. (2017). LRRK2 levels in immune cells are increased in Parkinson\u2019s disease. NPJ Parkinsons Disease, 3, 11. https:\/\/doi.org\/10.1038\/s41531-017-0010-8.","journal-title":"NPJ Parkinsons Disease"},{"issue":"7","key":"8619_CR8","doi-asserted-by":"publisher","first-page":"e22489","DOI":"10.1371\/journal.pone.0022489","volume":"6","author":"MJ Devine","year":"2011","unstructured":"Devine, M. J., Kaganovich, A., Ryten, M., Mamais, A., Trabzuni, D., Manzoni, C., et al. (2011). Pathogenic LRRK2 mutations do not alter gene expression in cell model systems or human brain tissue. PLoS ONE, 6(7), e22489. https:\/\/doi.org\/10.1371\/journal.pone.0022489.","journal-title":"PLoS ONE"},{"issue":"10","key":"8619_CR9","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s10072-016-2647-1","volume":"37","author":"E Dursun","year":"2016","unstructured":"Dursun, E., Alaylioglu, M., Bilgic, B., Hanagasi, H., Lohmann, E., Atasoy, I. L., et al. (2016). Vitamin D deficiency might pose a greater risk for ApoEvarepsilon4 non-carrier Alzheimer\u2019s disease patients. Neurological Sciences, 37(10), 1633\u20131643. https:\/\/doi.org\/10.1007\/s10072-016-2647-1.","journal-title":"Neurological Sciences"},{"issue":"2","key":"8619_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3233\/JAD-2010-101377","volume":"23","author":"E Dursun","year":"2011","unstructured":"Dursun, E., Gezen-Ak, D., & Yilmazer, S. (2011). A novel perspective for Alzheimer\u2019s disease: Vitamin D receptor suppression by amyloid-beta and preventing the amyloid-beta induced alterations by vitamin D in cortical neurons. Journal of Alzheimer\u2019s Disease, 23(2), 207\u2013219. https:\/\/doi.org\/10.3233\/JAD-2010-101377.","journal-title":"Journal of Alzheimer\u2019s Disease"},{"issue":"2","key":"8619_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3233\/JPD-130174","volume":"3","author":"N Dzamko","year":"2013","unstructured":"Dzamko, N., Chua, G., Ranola, M., Rowe, D. B., & Halliday, G. M. (2013). Measurement of LRRK2 and Ser910\/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic Parkinson\u2019s disease patients. Journal of Alzheimer\u2019s Disease, 3(2), 145\u2013152. https:\/\/doi.org\/10.3233\/JPD-130174.","journal-title":"Journal of Alzheimer\u2019s Disease"},{"issue":"3","key":"8619_CR12","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/ana.10113","volume":"51","author":"M Funayama","year":"2002","unstructured":"Funayama, M., Hasegawa, K., Kowa, H., Saito, M., Tsuji, S., & Obata, F. (2002). A new locus for Parkinson\u2019s disease (PARK8) maps to chromosome 12p11.2-q13.1. Annals of Neurology, 51(3), 296\u2013301. https:\/\/doi.org\/10.1002\/ana.10113.","journal-title":"Annals of Neurology"},{"issue":"4","key":"8619_CR13","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/ana.20808","volume":"59","author":"D Galter","year":"2006","unstructured":"Galter, D., Westerlund, M., Carmine, A., Lindqvist, E., Sydow, O., & Olson, L. (2006). LRRK2 expression linked to dopamine-innervated areas. Annals of Neurology, 59(4), 714\u2013719. https:\/\/doi.org\/10.1002\/ana.20808.","journal-title":"Annals of Neurology"},{"issue":"6","key":"8619_CR14","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/jnr.21949","volume":"87","author":"PN Gandhi","year":"2009","unstructured":"Gandhi, P. N., Chen, S. G., & Wilson-Delfosse, A. L. (2009). Leucine-rich repeat kinase 2 (LRRK2): A key player in the pathogenesis of Parkinson\u2019s disease. Journal of Neuroscience Research, 87(6), 1283\u20131295. https:\/\/doi.org\/10.1002\/jnr.21949.","journal-title":"Journal of Neuroscience Research"},{"issue":"1","key":"8619_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12017-016-8415-9","volume":"19","author":"D Gezen-Ak","year":"2017","unstructured":"Gezen-Ak, D., Alaylioglu, M., Genc, G., Gunduz, A., Candas, E., Bilgic, B., et al. (2017). GC and VDR SNPs and vitamin D levels in Parkinson\u2019s disease: The relevance to clinical features. NeuroMolecular Medicine, 19(1), 24\u201340. https:\/\/doi.org\/10.1007\/s12017-016-8415-9.","journal-title":"NeuroMolecular Medicine"},{"key":"8619_CR16","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-191164","author":"D Gezen-Ak","year":"2020","unstructured":"Gezen-Ak, D., Alaylioglu, M., Genc, G., Sengul, B., Keskin, E., Sordu, P., et al. (2020). Altered transcriptional profile of mitochondrial DNA-encoded OXPHOS subunits, mitochondria quality control genes, and \u0131ntracellular ATP levels in blood samples of patients with Parkinson\u2019s disease. Journal of Alzheimer\u2019s Disease. https:\/\/doi.org\/10.3233\/JAD-191164.","journal-title":"Journal of Alzheimer\u2019s Disease"},{"issue":"3","key":"8619_CR17","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s12017-018-8498-6","volume":"20","author":"D Gezen-Ak","year":"2018","unstructured":"Gezen-Ak, D., Atasoy, I. L., Candas, E., Alaylioglu, M., & Dursun, E. (2018). The transcriptional regulatory properties of amyloid beta 1-42 may \u0131nclude regulation of genes related to neurodegeneration. NeuroMolecular Medicine, 20(3), 363\u2013375. https:\/\/doi.org\/10.1007\/s12017-018-8498-6.","journal-title":"NeuroMolecular Medicine"},{"issue":"3","key":"8619_CR18","doi-asserted-by":"publisher","first-page":"e17553","DOI":"10.1371\/journal.pone.0017553","volume":"6","author":"D Gezen-Ak","year":"2011","unstructured":"Gezen-Ak, D., Dursun, E., & Yilmazer, S. (2011). The effects of vitamin D receptor silencing on the expression of LVSCC-A1C and LVSCC-A1D and the release of NGF in cortical neurons. PLoS ONE, 6(3), e17553. https:\/\/doi.org\/10.1371\/journal.pone.0017553.","journal-title":"PLoS ONE"},{"issue":"9","key":"8619_CR19","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/mds.20213","volume":"19","author":"CG Goetz","year":"2004","unstructured":"Goetz, C. G., Poewe, W., Rascol, O., Sampaio, C., Stebbins, G. T., Counsell, C., et al. (2004). Movement disorder society task force report on the Hoehn and Yahr staging scale: Status and recommendations. Movement Disorders, 19(9), 1020\u20131028. https:\/\/doi.org\/10.1002\/mds.20213.","journal-title":"Movement Disorders"},{"issue":"5","key":"8619_CR20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn, M. M., & Yahr, M. D. (1967). Parkinsonism: Onset, progression and mortality. Neurology, 17(5), 427\u2013442.","journal-title":"Neurology"},{"issue":"7","key":"8619_CR21","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/mds.21477","volume":"22","author":"Y Huang","year":"2007","unstructured":"Huang, Y., Halliday, G. M., Vandebona, H., Mellick, G. D., Mastaglia, F., Stevens, J., et al. (2007). Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson\u2019s disease. Movement Disorders, 22(7), 982\u2013989. https:\/\/doi.org\/10.1002\/mds.21477.","journal-title":"Movement Disorders"},{"issue":"214","key":"8619_CR22","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.1016\/j.neurobiolaging.2015.10.026","volume":"38","author":"J Infante","year":"2016","unstructured":"Infante, J., Prieto, C., Sierra, M., Sanchez-Juan, P., Gonzalez-Aramburu, I., Sanchez-Quintana, C., et al. (2016). Comparative blood transcriptome analysis in idiopathic and LRRK2 G2019S-associated Parkinson\u2019s disease. Neurobiology of Aging, 38(214), e211\u2013e215. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2015.10.026.","journal-title":"Neurobiology of Aging"},{"issue":"1","key":"8619_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/mds.21180","volume":"22","author":"L Ishihara","year":"2007","unstructured":"Ishihara, L., Gibson, R. A., Warren, L., Amouri, R., Lyons, K., Wielinski, C., et al. (2007). Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson\u2019s disease families. Movement Disorders, 22(1), 55\u201361. https:\/\/doi.org\/10.1002\/mds.21180.","journal-title":"Movement Disorders"},{"issue":"4","key":"8619_CR24","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/jcla.21769","volume":"29","author":"E Jiang","year":"2015","unstructured":"Jiang, E., Li, F., Jing, C., Li, P., Cui, H., Wang, B., et al. (2015). High-resolution melting analysis as a developed method for genotyping the PD susceptibility loci in LRRK2 gene. Journal of Clinical Laboratory Analysis, 29(4), 299\u2013304. https:\/\/doi.org\/10.1002\/jcla.21769.","journal-title":"Journal of Clinical Laboratory Analysis"},{"issue":"1","key":"8619_CR25","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1001\/jamaneurol.2014.2704","volume":"72","author":"LV Kalia","year":"2015","unstructured":"Kalia, L. V., Lang, A. E., Hazrati, L. N., Fujioka, S., Wszolek, Z. K., Dickson, D. W., et al. (2015). Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurology, 72(1), 100\u2013105. https:\/\/doi.org\/10.1001\/jamaneurol.2014.2704.","journal-title":"JAMA Neurology"},{"issue":"5","key":"8619_CR26","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/ane.12563","volume":"134","author":"K Kalinderi","year":"2016","unstructured":"Kalinderi, K., Bostantjopoulou, S., & Fidani, L. (2016). The genetic background of Parkinson\u2019s disease: Current progress and future prospects. Acta Neurologica Scandinavica, 134(5), 314\u2013326. https:\/\/doi.org\/10.1111\/ane.12563.","journal-title":"Acta Neurologica Scandinavica"},{"issue":"Pt 12","key":"8619_CR27","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1093\/brain\/awh667","volume":"128","author":"NL Khan","year":"2005","unstructured":"Khan, N. L., Jain, S., Lynch, J. M., Pavese, N., Abou-Sleiman, P., Holton, J. L., et al. (2005). Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson\u2019s disease: Clinical, pathological, olfactory and functional imaging and genetic data. Brain, 128(Pt 12), 2786\u20132796. https:\/\/doi.org\/10.1093\/brain\/awh667.","journal-title":"Brain"},{"issue":"22","key":"8619_CR28","doi-asserted-by":"publisher","first-page":"6455","DOI":"10.1111\/j.1742-4658.2009.07344.x","volume":"276","author":"U Kumari","year":"2009","unstructured":"Kumari, U., & Tan, E. K. (2009). LRRK2 in Parkinson\u2019s disease: Genetic and clinical studies from patients. FEBS Journal, 276(22), 6455\u20136463. https:\/\/doi.org\/10.1111\/j.1742-4658.2009.07344.x.","journal-title":"FEBS Journal"},{"issue":"R1","key":"8619_CR29","doi-asserted-by":"publisher","first-page":"R48","DOI":"10.1093\/hmg\/ddp012","volume":"18","author":"S Lesage","year":"2009","unstructured":"Lesage, S., & Brice, A. (2009). Parkinson\u2019s disease: From monogenic forms to genetic susceptibility factors. Human Molecular Genetics, 18(R1), R48\u2013R59. https:\/\/doi.org\/10.1093\/hmg\/ddp012.","journal-title":"Human Molecular Genetics"},{"issue":"2","key":"8619_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.patbio.2006.06.001","volume":"55","author":"S Lesage","year":"2007","unstructured":"Lesage, S., Durr, A., & Brice, A. (2007). LRRK2: A link between familial and sporadic Parkinson\u2019s disease? Pathologie Biologie, 55(2), 107\u2013110. https:\/\/doi.org\/10.1016\/j.patbio.2006.06.001.","journal-title":"Pathologie Biologie"},{"key":"8619_CR31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1750-1326-9-47","volume":"9","author":"JQ Li","year":"2014","unstructured":"Li, J. Q., Tan, L., & Yu, J. T. (2014). The role of the LRRK2 gene in Parkinsonism. Molecular Neurodegeneration, 9, 47. https:\/\/doi.org\/10.1186\/1750-1326-9-47.","journal-title":"Molecular Neurodegeneration"},{"issue":"9","key":"8619_CR32","doi-asserted-by":"publisher","first-page":"e75041","DOI":"10.1371\/journal.pone.0075041","volume":"8","author":"H Li","year":"2013","unstructured":"Li, H., Teo, Y. Y., & Tan, E. K. (2013). Patterns of linkage disequilibrium of LRRK2 across different races: Implications for genetic association studies. PLoS ONE, 8(9), e75041. https:\/\/doi.org\/10.1371\/journal.pone.0075041.","journal-title":"PLoS ONE"},{"issue":"1","key":"8619_CR33","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/mds.23968","volume":"27","author":"O Lorenzo-Betancor","year":"2012","unstructured":"Lorenzo-Betancor, O., Samaranch, L., Ezquerra, M., Tolosa, E., Lorenzo, E., Irigoyen, J., et al. (2012). LRRK2 haplotype-sharing analysis in Parkinson\u2019s disease reveals a novel p.S1761R mutation. Movement Disorders, 27(1), 146\u2013151. https:\/\/doi.org\/10.1002\/mds.23968.","journal-title":"Movement Disorders"},{"issue":"9","key":"8619_CR34","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1002\/jnr.21656","volume":"86","author":"YW Lu","year":"2008","unstructured":"Lu, Y. W., & Tan, E. K. (2008). Molecular biology changes associated with LRRK2 mutations in Parkinson\u2019s disease. Journal of Neuroscience Research, 86(9), 1895\u20131901. https:\/\/doi.org\/10.1002\/jnr.21656.","journal-title":"Journal of Neuroscience Research"},{"issue":"14","key":"8619_CR35","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1002\/mds.25226","volume":"27","author":"IF Mata","year":"2012","unstructured":"Mata, I. F., Checkoway, H., Hutter, C. M., Samii, A., Roberts, J. W., Kim, H. M., et al. (2012). Common variation in the LRRK2 gene is a risk factor for Parkinson\u2019s disease. Movement Disorders, 27(14), 1822\u20131825. https:\/\/doi.org\/10.1002\/mds.25226.","journal-title":"Movement Disorders"},{"issue":"14","key":"8619_CR36","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1002\/mds.25226","volume":"27","author":"IF Mata","year":"2013","unstructured":"Mata, I. F., Checkoway, H., Hutter, C. M., Samii, A., Roberts, J. W., Kim, H. M., et al. (2013). Common variation in the LRRK2 gene is a risk factor for Parkinson\u2019s disease. Movement Disorders, 27(14), 1822\u20131825. https:\/\/doi.org\/10.1002\/mds.25226.","journal-title":"Movement Disorders"},{"issue":"10","key":"8619_CR37","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1097\/01.jnen.0000235121.98052.54","volume":"65","author":"J Miklossy","year":"2006","unstructured":"Miklossy, J., Arai, T., Guo, J. P., Klegeris, A., Yu, S., McGeer, E. G., et al. (2006). LRRK2 expression in normal and pathologic human brain and in human cell lines. Journal of Neuropathology and Experimental Neurology, 65(10), 953\u2013963. https:\/\/doi.org\/10.1097\/01.jnen.0000235121.98052.54.","journal-title":"Journal of Neuropathology and Experimental Neurology"},{"issue":"4","key":"8619_CR38","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.neuron.2004.10.023","volume":"44","author":"C Paisan-Ruiz","year":"2004","unstructured":"Paisan-Ruiz, C., Jain, S., Evans, E. W., Gilks, W. P., Simon, J., van der Brug, M., et al. (2004). Cloning of the gene containing mutations that cause PARK8-linked Parkinson\u2019s disease. Neuron, 44(4), 595\u2013600. https:\/\/doi.org\/10.1016\/j.neuron.2004.10.023.","journal-title":"Neuron"},{"issue":"4","key":"8619_CR39","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/humu.20668","volume":"29","author":"C Paisan-Ruiz","year":"2008","unstructured":"Paisan-Ruiz, C., Nath, P., Washecka, N., Gibbs, J. R., & Singleton, A. B. (2008). Comprehensive analysis of LRRK2 in publicly available Parkinson\u2019s disease cases and neurologically normal controls. Human Mutation, 29(4), 485\u2013490. https:\/\/doi.org\/10.1002\/humu.20668.","journal-title":"Human Mutation"},{"issue":"29","key":"8619_CR40","doi-asserted-by":"publisher","first-page":"8263","DOI":"10.1007\/s00216-016-9936-7","volume":"408","author":"R Pan","year":"2016","unstructured":"Pan, R., & Xiao, P. (2016). Quantitative haplotyping of PCR products by nonsynchronous pyrosequencing with di-base addition. Analytical and Bioanalytical Chemistry, 408(29), 8263\u20138271. https:\/\/doi.org\/10.1007\/s00216-016-9936-7.","journal-title":"Analytical and Bioanalytical Chemistry"},{"issue":"3","key":"8619_CR41","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.parkreldis.2008.05.004","volume":"15","author":"B Patra","year":"2009","unstructured":"Patra, B., Parsian, A. J., Racette, B. A., Zhao, J. H., Perlmutter, J. S., & Parsian, A. (2009). LRRK2 gene G2019S mutation and SNPs [haplotypes] in subtypes of Parkinson\u2019s disease. Parkinsonism & Related Disorders, 15(3), 175\u2013180. https:\/\/doi.org\/10.1016\/j.parkreldis.2008.05.004.","journal-title":"Parkinsonism & Related Disorders"},{"issue":"10","key":"8619_CR42","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/S1474-4422(11)70175-2","volume":"10","author":"OA Ross","year":"2011","unstructured":"Ross, O. A., Soto-Ortolaza, A. I., Heckman, M. G., Aasly, J. O., Abahuni, N., Annesi, G., et al. (2011). Association of LRRK2 exonic variants with susceptibility to Parkinson\u2019s disease: A case-control study. The Lancet Neurology, 10(10), 898\u2013908. https:\/\/doi.org\/10.1016\/S1474-4422(11)70175-2.","journal-title":"The Lancet Neurology"},{"issue":"12","key":"8619_CR43","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1002\/mds.23163","volume":"25","author":"OA Ross","year":"2010","unstructured":"Ross, O. A., Wilhoite, G. J., Bacon, J. A., Soto-Ortolaza, A., Kachergus, J., Cobb, S. A., et al. (2010). LRRK2 variation and Parkinson\u2019s disease in African Americans. Movement Disorders, 25(12), 1973\u20131976. https:\/\/doi.org\/10.1002\/mds.23163.","journal-title":"Movement Disorders"},{"issue":"9","key":"8619_CR44","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/archneur.63.9.1225","volume":"63","author":"AH Schapira","year":"2006","unstructured":"Schapira, A. H. (2006). The importance of LRRK2 mutations in Parkinson disease. Archives of Neurology, 63(9), 1225\u20131228. https:\/\/doi.org\/10.1001\/archneur.63.9.1225.","journal-title":"Archives of Neurology"},{"issue":"1","key":"8619_CR45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40478-018-0561-x","volume":"6","author":"M Schulze","year":"2018","unstructured":"Schulze, M., Sommer, A., Plotz, S., Farrell, M., Winner, B., Grosch, J., et al. (2018). Sporadic Parkinson\u2019s disease derived neuronal cells show disease-specific mRNA and small RNA signatures with abundant deregulation of piRNAs. Acta Neuropathologica Communications, 6(1), 58. https:\/\/doi.org\/10.1186\/s40478-018-0561-x.","journal-title":"Acta Neuropathologica Communications"},{"issue":"7","key":"8619_CR46","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/j.1365-2990.2011.01187.x","volume":"37","author":"S Sharma","year":"2011","unstructured":"Sharma, S., Bandopadhyay, R., Lashley, T., Renton, A. E., Kingsbury, A. E., Kumaran, R., et al. (2011). LRRK2 expression in idiopathic and G2019S positive Parkinson\u2019s disease subjects: A morphological and quantitative study. Neuropathology and Applied Neurobiology, 37(7), 777\u2013790. https:\/\/doi.org\/10.1111\/j.1365-2990.2011.01187.x.","journal-title":"Neuropathology and Applied Neurobiology"},{"issue":"Pt 7","key":"8619_CR47","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1093\/brain\/awn323","volume":"132","author":"F Simunovic","year":"2009","unstructured":"Simunovic, F., Yi, M., Wang, Y., Macey, L., Brown, L. T., Krichevsky, A. M., et al. (2009). Gene expression profiling of substantia nigra dopamine neurons: Further insights into Parkinson\u2019s disease pathology. Brain, 132(Pt 7), 1795\u20131809. https:\/\/doi.org\/10.1093\/brain\/awn323.","journal-title":"Brain"},{"issue":"1","key":"8619_CR48","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mds.25249","volume":"28","author":"AB Singleton","year":"2013","unstructured":"Singleton, A. B., Farrer, M. J., & Bonifati, V. (2013). The genetics of Parkinson\u2019s disease: Progress and therapeutic implications. Movement Disorders, 28(1), 14\u201323. https:\/\/doi.org\/10.1002\/mds.25249.","journal-title":"Movement Disorders"},{"issue":"4","key":"8619_CR49","first-page":"287","volume":"2","author":"AI Soto-Ortolaza","year":"2013","unstructured":"Soto-Ortolaza, A. I., Heckman, M. G., Labbe, C., Serie, D. J., Puschmann, A., Rayaprolu, S., et al. (2013). GWAS risk factors in Parkinson\u2019s disease: LRRK2 coding variation and genetic interaction with PARK16. American Journal of Neurodegenerative Disease, 2(4), 287\u2013299.","journal-title":"American Journal of Neurodegenerative Disease"},{"issue":"Suppl 1","key":"8619_CR50","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/S1353-8020(13)70011-7","volume":"20","author":"M Spatola","year":"2014","unstructured":"Spatola, M., & Wider, C. (2014). Genetics of Parkinson\u2019s disease: The yield. Parkinsonism & Related Disorders, 20(Suppl 1), S35\u2013S38. https:\/\/doi.org\/10.1016\/S1353-8020(13)70011-7.","journal-title":"Parkinsonism & Related Disorders"},{"issue":"6","key":"8619_CR51","doi-asserted-by":"publisher","first-page":"e21519","DOI":"10.1371\/journal.pone.0021519","volume":"6","author":"J Thevenet","year":"2011","unstructured":"Thevenet, J., Pescini Gobert, R., Hooft van Huijsduijnen, R., Wiessner, C., & Sagot, Y. J. (2011). Regulation of LRRK2 expression points to a functional role in human monocyte maturation. PLoS ONE, 6(6), e21519. https:\/\/doi.org\/10.1371\/journal.pone.0021519.","journal-title":"PLoS ONE"},{"issue":"4","key":"8619_CR52","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","volume":"44","author":"A Zimprich","year":"2004","unstructured":"Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., et al. (2004). Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron, 44(4), 601\u2013607. https:\/\/doi.org\/10.1016\/j.neuron.2004.11.005.","journal-title":"Neuron"}],"container-title":["NeuroMolecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12017-020-08619-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12017-020-08619-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12017-020-08619-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T23:10:45Z","timestamp":1633389045000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12017-020-08619-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,4]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["8619"],"URL":"https:\/\/doi.org\/10.1007\/s12017-020-08619-x","relation":{},"ISSN":["1535-1084","1559-1174"],"issn-type":[{"type":"print","value":"1535-1084"},{"type":"electronic","value":"1559-1174"}],"subject":[],"published":{"date-parts":[[2020,10,4]]},"assertion":[{"value":"2 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Participants in the present study were treated according to the ethical principles for medical research involving human participants described in the World Medical Association\u2019s Declaration of Helsinki, and the study was approved by the Ethics Committee of Istanbul University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Signed informed consent was obtained from all study participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}